IRWD On Watch, Eagle Hurt As Study Fails, NCNA Down Over 30% This Month

(RTTNews) - The following are some of the pharma/biotech stocks that posted the biggest percentage decline today.

1. vTv Therapeutics Inc. (VTVT)

Lost 18.97% to close Tuesday's (Oct.30) trading at $2.35.

News: The Company's securities were transferred from the Nasdaq Global Market to the Nasdaq Capital Market at the opening of business on October 30, 2018.

There are three tiers of Nasdaq listing - the Global Select Market, Global Market and Capital Market.

Recent event:

-- On October 24, the Company announced positive results of a subgroup analysis from its phase III STEADFAST trial, indicating potential benefit of treatment with Azeliragon for patients with Type 2 Diabetes and Alzheimer's disease.

The STEADFAST is a phase III trial that evaluated Azeliragon in patients with mild Alzheimer's disease. The STEADFAST trial had 2 parts - Part A and Part B. Part A enrolled patients in the United States and Canada. Part B included study sites in the United Kingdom, Ireland, Australia, New Zealand and South Africa.

In June of this year, the Company announced disappointing results from Part B of STEADFAST Study. The results from Part A of the STEADFAST study, announced in April 2018, were also disappointing.

2. Ironwood Pharmaceuticals Inc. (IRWD)

Lost 18.09% to close Tuesday's trading at $13.18.

News: No news

Near-term Catalyst:

The Company is slated to announce third quarter financial results on November 6, 2018.

3. Eagle Pharmaceuticals Inc. (EGRX)

Lost 16.52% to close Tuesday's trading at $47.50.

News: A pharmacokinetic and safety study comparing the Company's formulation of fulvestrant against AstraZeneca's breast cancer drug Faslodex did not meet the primary bioequivalence endpoints. The study was conducted in 600 healthy female volunteers across multiple U.S. sites.

The Company also provided preliminary Q3, 2018 financial results and announced that its Board of Directors has approved a new stock repurchase program providing for the repurchase of up to an aggregate of $150 million of Eagle's common stock.

Q3 2018 preliminary adjusted Non-GAAP EPS is expected to be $1.18 per share, well above analysts' expectation of $0.98 per share.

The Company will release its 2018 third quarter financial results on Thursday, November 1, 2018, before the market opens.

4. AAC Holdings Inc. (AAC)

American Addiction Centers is a provider of inpatient substance abuse treatment services.

Lost 16.51% to close Tuesday's trading at $5.46.

News: No news

Near-term Catalyst:

The Company is expected to issue its earnings release before the market opens on Tuesday, November 6, 2018.

5. NuCana plc (NCNA)

NuCana is a clinical-stage biopharmaceutical company focused on improving treatment outcomes for patients with cancer.

Lost 12.11% to close Tuesday's trading at $17.12.

News: No news

Clinical Trials & Near-term Catalysts:

The Company's product candidates are Acelarin and NUC-3373.

Acelarin is currently being evaluated in the indications of ovarian cancer, biliary cancer and pancreatic cancer.

A phase II study evaluating single-agent Acelarin in patients with platinum-resistant ovarian cancer; a phase III trial comparing Acelarin with gemcitabine for people with pancreatic cancer, dubbed ACELARATE, a phase I study of Acelarin with cisplatin for bile duct cancer, and a phase Ib study of Acelarin and Carboplatin for patients with recurrent ovarian cancer are also underway.

-- NUC-3373 is currently in a Phase 1 study for the potential treatment of a wide range of advanced solid tumor cancers. -- A phase Ib study of NUC-3373 in patients with advanced colorectal cancer in combination with other approved agents with which 5-FU is typically combined, including leucovorin, oxaliplatin and irinotecan is also being planned. -- A First-In-Human phase I clinical study of NUC-7738 in patients with solid tumors is expected to be initiated later in 2018.